Ospemifene is an oral medication indicated for the treatment of dyspareunia, pain during sexual intercourse, encountered by some women, more often in those who are post-menopausal. Chemically classified as a selective estrogen receptor modulator, ospemifene exhibits tissue-selective estrogen receptor activity with clinically relevant estrogen agonist effects on the vaginal epithelium that restore superficial cell layers and reduce vaginal pH, improving lubrication and reducing pain. The approved oral dose is 60 mg once daily taken with food. After oral administration peak plasma concentrations are reached within about 1.5 to 3 hours and the terminal half-life supports once-daily dosing. Ospemifene is highly protein bound, undergoes hepatic metabolism including CYP3A4 and CYP2C9 pathways, and is eliminated via feces and urine; active metabolites contribute to pharmacodynamic activity. Clinically relevant safety considerations include thromboembolic risk similar to other estrogen receptor modulators, potential effects on the endometrium that warrant monitoring of abnormal bleeding, and contraindications in patients with current or past estrogen-dependent malignancies or history of venous thromboembolism.
Parent: Ospemifene
Parent: Ospemifene
Typical specification limits for ospemifene active pharmaceutical ingredient include analytical thresholds for related substances and impurities to ensure quality and safety. Common commercial and regulatory specifications set individual known related impurities not greater than 0.5 percent weight by weight as measured by validated HPLC area percent, individual unidentified impurities not greater than 0.10 percent w/w, and total impurities not greater than 2.0 percent w/w. Genotoxic and mutagenic impurities are controlled per ICH M7 guidance with qualification or specific limits in the low parts-per-million range where applicable. Residual solvents are controlled according to ICH Q3C with class-specific limits and elemental impurities are controlled according to ICH Q3D, typically with elemental metal limits reported in parts per million. Analytical control methods include reversed-phase liquid chromatography with UV detection, mass spectrometry for identification, and stability-indicating assays to monitor impurity profiles over shelf life.
Ospemifene binds to estrogen receptors ERalpha and ERbeta and acts as a selective estrogen receptor modulator, producing estrogen agonist effects in the vaginal epithelium that increase epithelial maturation and secretions while exhibiting tissue-selective antagonist or mixed activity in other tissues. The pharmacologic effect on the vaginal mucosa relieves symptoms attributable to vulvar and vaginal atrophy.
Ospemifene is indicated for the treatment of dyspareunia due to vulvar and vaginal atrophy in postmenopausal women. The recommended regimen is 60 mg orally once daily with food, and use should follow evaluation of risks and benefits for the individual patient.
Safety is context dependent and cannot be universally stated as safer. Ospemifene is not a conventional systemic estrogen and has tissue-selective effects, but it shares some risk profiles with estrogenic therapies, including an increased risk of venous thromboembolism and possible effects on the endometrium. Comparative safety versus systemic estrogen products depends on dose, duration, patient risk factors, and monitoring. Treatment decisions should be individualized in consultation with a clinician.
Cost varies by country, pharmacy, insurance coverage, and whether a branded product or generic is obtained. As a general range, branded product retail prices in the United States have historically been in the low hundreds of US dollars for a one-month supply, while generic formulations and insurance-covered prescriptions may reduce out-of-pocket costs substantially. For an accurate current price obtain a pharmacy quote or check formulary and discount programs.
